Concepedia

Ryan Stansfield

RS

Statistics

Publications

11

Citations

1K

H-Index

10

Active since

1990

Affiliations

University of Chicago(Current)

Bristol-Myers Squibb (Switzerland)

Cytel (United States)

Ryan Stansfield is an author at University of Chicago specializing in pharmacology, drug discovery, and medicinal chemistry.

Publications per year

1990–2020

11

Publications

11

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Fabrice Pierre, Peter Chua, Sean O’Brien et al. · Journal of Medicinal Chemistry · 2010 · 299 citations · Full text

, , +15

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

Mustapha Haddach, Michael K. Schwaebe, Jerome Michaux et al. · ACS Medicinal Chemistry Letters · 2012 · 164 citations

, , +14

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Fabrice Pierre, Peter Chua, Sean O’Brien et al. · Molecular and Cellular Biochemistry · 2011 · 155 citations

, , +4

Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)

Toufike Kanouni, Christophe Severin, Robert W. Cho et al. · Journal of Medicinal Chemistry · 2020 · 120 citations · Full text

, , +13

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor

Mustapha Haddach, Jerome Michaux, Michael K. Schwaebe et al. · ACS Medicinal Chemistry Letters · 2011 · 86 citations · Full text

, , +10

1–5 of 11